Literature DB >> 23352636

A rapid ultra HPLC-MS/MS method for the quantitation and pharmacokinetic analysis of 3-deazaneplanocin A in mice.

Cody J Peer1, Mahadev Rao, Shawn D Spencer, Shandiz Shahbazi, Patricia S Steeg, David S Schrump, William D Figg.   

Abstract

3-Deazaneplanocin A (DZNep) has been shown to have anti-cancer activity in numerous cancer types and its continued preclinical, and eventual clinical, drug development will require rapid and sensitive bioanalytical methods in order to quantitate this drug for pharmacokinetic analyses. The ultra HPLC with positive thermospray tandem mass spectrometric (LC-MS/MS) detection affords the most sensitive (limit of quantitation 5ng/mL) and rapid (3min run time) bioanalytical method to date for DZNep. Due to the polar nature of this drug and the internal standard (tubercidin), a hydrophilic-interaction column (HILIC) was used. The method was accurate, with less than 10% deviation from nominal values, as well as precise, where both within-day and between-day precisions were less than 15%. A liquid-liquid extraction procedure was able to recover ∼90% of drug from a small volume (50μL) of mouse plasma. This method was successfully applied to a pharmacokinetic study in mice intravenously injected with DZNep. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23352636      PMCID: PMC3640617          DOI: 10.1016/j.jchromb.2013.01.003

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  25 in total

Review 1.  The history of cancer epigenetics.

Authors:  Andrew P Feinberg; Benjamin Tycko
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

2.  Loading 3-deazaneplanocin A into pegylated unilamellar liposomes by forming transient phenylboronic acid-drug complex and its pharmacokinetic features in Sprague-Dawley rats.

Authors:  Feng Sun; Jian Li; Qiang Yu; Eli Chan
Journal:  Eur J Pharm Biopharm       Date:  2011-10-28       Impact factor: 5.571

3.  Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer.

Authors:  Mario F Fraga; Esteban Ballestar; Ana Villar-Garea; Manuel Boix-Chornet; Jesus Espada; Gunnar Schotta; Tiziana Bonaldi; Claire Haydon; Santiago Ropero; Kevin Petrie; N Gopalakrishna Iyer; Alberto Pérez-Rosado; Enrique Calvo; Juan A Lopez; Amparo Cano; Maria J Calasanz; Dolors Colomer; Miguel Angel Piris; Natalie Ahn; Axel Imhof; Carlos Caldas; Thomas Jenuwein; Manel Esteller
Journal:  Nat Genet       Date:  2005-03-13       Impact factor: 38.330

4.  EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.

Authors:  Ingeborg M Bachmann; Ole J Halvorsen; Karin Collett; Ingunn M Stefansson; Oddbjørn Straume; Svein A Haukaas; Helga B Salvesen; Arie P Otte; Lars A Akslen
Journal:  J Clin Oncol       Date:  2005-12-05       Impact factor: 44.544

5.  The polycomb group protein EZH2 is involved in progression of prostate cancer.

Authors:  Sooryanarayana Varambally; Saravana M Dhanasekaran; Ming Zhou; Terrence R Barrette; Chandan Kumar-Sinha; Martin G Sanda; Debashis Ghosh; Kenneth J Pienta; Richard G A B Sewalt; Arie P Otte; Mark A Rubin; Arul M Chinnaiyan
Journal:  Nature       Date:  2002-10-10       Impact factor: 49.962

6.  Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker.

Authors:  Masashi Takawa; Ken Masuda; Masaki Kunizaki; Yataro Daigo; Katsunori Takagi; Yukiko Iwai; Hyun-Soo Cho; Gouji Toyokawa; Yuka Yamane; Kazuhiro Maejima; Helen I Field; Takaaki Kobayashi; Takayuki Akasu; Masanori Sugiyama; Eijyu Tsuchiya; Yutaka Atomi; Bruce A J Ponder; Yusuke Nakamura; Ryuji Hamamoto
Journal:  Cancer Sci       Date:  2011-05-26       Impact factor: 6.716

7.  Pharmacokinetics of the antiviral agent 3-deazaneplanocin A.

Authors:  R A Coulombe; R P Sharma; J W Huggins
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Jul-Sep       Impact factor: 2.441

Review 8.  The fundamental role of epigenetic events in cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Nat Rev Genet       Date:  2002-06       Impact factor: 53.242

9.  Polycomb repressor complex-2 is a novel target for mesothelioma therapy.

Authors:  Clinton D Kemp; Mahadev Rao; Sichuan Xi; Suzanne Inchauste; Haresh Mani; Patricia Fetsch; Armando Filie; Mary Zhang; Julie A Hong; Robert L Walker; Yuelin J Zhu; R Taylor Ripley; Aarti Mathur; Fang Liu; Maocheng Yang; Paul A Meltzer; Victor E Marquez; Assunta De Rienzo; Raphael Bueno; David S Schrump
Journal:  Clin Cancer Res       Date:  2011-10-25       Impact factor: 12.531

10.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells.

Authors:  Celina G Kleer; Qi Cao; Sooryanarayana Varambally; Ronglai Shen; Ichiro Ota; Scott A Tomlins; Debashis Ghosh; Richard G A B Sewalt; Arie P Otte; Daniel F Hayes; Michael S Sabel; Donna Livant; Stephen J Weiss; Mark A Rubin; Arul M Chinnaiyan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-19       Impact factor: 11.205

View more
  2 in total

1.  Inhibition of EZH2 prevents fibrosis and restores normal angiogenesis in scleroderma.

Authors:  Pei-Suen Tsou; Phillip Campbell; M Asif Amin; Patrick Coit; Shaylynn Miller; David A Fox; Dinesh Khanna; Amr H Sawalha
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-12       Impact factor: 11.205

2.  Attenuation of SARS-CoV-2 replication and associated inflammation by concomitant targeting of viral and host cap 2'-O-ribose methyltransferases.

Authors:  Valter Bergant; Shintaro Yamada; Vincent Grass; Yuta Tsukamoto; Teresa Lavacca; Karsten Krey; Maria-Teresa Mühlhofer; Sabine Wittmann; Armin Ensser; Alexandra Herrmann; Anja Vom Hemdt; Yuriko Tomita; Shutoku Matsuyama; Takatsugu Hirokawa; Yiqi Huang; Antonio Piras; Constanze A Jakwerth; Madlen Oelsner; Susanne Thieme; Alexander Graf; Stefan Krebs; Helmut Blum; Beate M Kümmerer; Alexey Stukalov; Carsten B Schmidt-Weber; Manabu Igarashi; Thomas Gramberg; Andreas Pichlmair; Hiroki Kato
Journal:  EMBO J       Date:  2022-07-25       Impact factor: 14.012

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.